The global small intestinal bacterial overgrowth diagnostics market was valued at USD 1,38,324.2 Thousand in 2022 and it is anticipated to grow up to USD 2,44,337.1 Thousand by 2032, at a CAGR of 5.9% during the forecast period.
Small intestinal bacterial overgrowth (SIBO) is defined as the presence of excessive bacteria in the small intestine. SIBO is frequently implicated as the cause of chronic diarrhea and malabsorption. Patients with SIBO may also suffer from unintentional weight loss, nutritional deficiencies, and osteoporosis.